29 completed, 8 unknown, 7 recruiting, 5 terminated. 57 Phase 2, 9 Phase 1, 2 Phase 3.
Follow Histiocytoma: new trials by email Literature Review of Histiocytoma trials Research Report on Histiocytoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Doxorubicin With or Without DT-7012 in Advanced Soft Tissue Sarcoma DT-7012, Doxorubicin - Undifferentiated Pleomorphic Sarcoma (UPS), Dedifferentiated Liposarcoma (DDLPS) | Phase 2 | Not yet recruiting | Gustave Roussy, Cancer Campus, Grand Paris | 80 | 2027-02-01 | 2026-09-15 |
| A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Soft Tissue Sarcoma Lifileucel - Sarcoma, Soft Tissue Sarcoma (STS) | Phase 2 | Recruiting | Iovance Biotherapeutics, Inc. | 80 | 2026-10-02 | 2026-10-09 |
| SBRT Combined With Reduced-Dose Anthracycline Chemotherapy and Toripalimab as Neoadjuvant Therapy for Localized High-Risk Undifferentiated Pleomorphic Sarcoma Toripalimab, Liposomal doxorubicin, Stereotactic body radiotherapy (SBRT) - Undifferentiated Pleomorphic Sarcoma (UPS) | Phase 2 | Not yet recruiting | Tianjin Medical University Cancer Institute and Hospital | 39 | 2026-09-01 | 2026-09-14 |
| Dose-escalated, Hypofractionated, Definitive Proton Radiotherapy for Patients With Inoperable Soft Tissue Sarcoma. Definitive radiotherapy - Soft Tissue Sarcoma (STS), Soft Tissue Sarcoma Adult | Phase 2 | Recruiting | Oslo University Hospital | 40 | 2026-01-26 | 2026-01-28 |
| Hypofractionated, 3-week, Preoperative Proton or X-ray Radiotherapy for Patients With Localized Soft Tissue Sarcoma preoperative, Quality of life, Functional outcome - Soft Tissue Sarcoma (Excluding GIST), Soft Tissue Sarcoma Adult | Phase 2 | Recruiting | Oslo University Hospital | 110 | 2026-01-26 | 2026-01-28 |
| MASCT-I Combined With Doxorubicin and Ifosfamide for First-line Treatment of Advanced Soft Tissue Sarcoma MASCT-I, Doxorubicin, Ifosfamide - Leiomyosarcoma, Liposarcoma | Phase 2 | Recruiting | HRYZ Biotech Co. | 148 | 2024-02-21 | 2025-07-24 |
| Testing Ipilimumab and Nivolumab Combination With or Without Cabozantinib in People >= 18 Years Old With Advanced Soft Tissue Sarcoma Biopsy Procedure, Biospecimen Collection, Cabozantinib - Locally Advanced Extraskeletal Myxoid Chondrosarcoma, Locally Advanced Leiomyosarcoma | Phase 2 | Active not recruiting | National Cancer Institute LAO | 66 | 2023-10-25 | 2026-10-09 |
| Combination of Pembrolizumab and Cabozantinib in Patients With Advanced Sarcomas Association of pembrolizumab + cabozantinib - Soft Tissue Sarcoma Adult, Advanced Soft-tissue Sarcoma | Phase 2 | Recruiting | Institut BergoniƩ | 119 | 2022-04-25 | 2025-10-07 |
| Phase 2 Study of 9-ING-41 With Chemotherapy in Sarcoma Gemcitabine, 9-ING-41, Docetaxel - Soft Tissue Sarcoma, Undifferentiated Pleomorphic Sarcoma | Phase 2 | Withdrawn | Brown University | 2022-03-01 | 2021-12-07 | |
| A Phase 2 Study of 9-ING-41Combined With Chemotherapy in Adolescents and Adults With Advanced Sarcomas Gemcitabine, Docetaxel, 9-ING-41 - Sarcoma, Soft Tissue Sarcoma | Phase 2 | Withdrawn | Brown University | 2021-09-01 | 2021-07-28 | |
| Propranolol and Pembrolizumab in Advanced Soft Tissue Sarcoma Patients Propranolol, Pembrolizumab - Soft Tissue Sarcoma Adult, Angiosarcoma | Phase 2 | Recruiting | Niels Junker | 80 | 2021-08-17 | 2023-07-27 |
| Sintilimab for the Treatment of Locally Advanced, Metastatic, Recurrent, or Unresectable Undifferentiated Pleomorphic Sarcoma, SiARa Cancer Study Sintilimab - Locally Advanced Undifferentiated Pleomorphic Sarcoma, Metastatic Undifferentiated Pleomorphic Sarcoma | Phase 2 | Terminated | M.D. Anderson Cancer Center | 6 | 2021-07-13 | 2024-12-11 |
| ENVASARC: Envafolimab And Envafolimab With Ipilimumab In Patients With Undifferentiated Pleomorphic Sarcoma Or Myxofibrosarcoma Envafolimab, Ipilimumab - Undifferentiated Pleomorphic Sarcoma, Myxofibrosarcoma | Phase 2 | Unknown | Tracon Pharmaceuticals Inc. | 207 | 2020-12-09 | 2024-05-17 |
| A Study of Pembrolizumab Plus Local Chemotherapy Using Isolated Limb Infusion (ILI) for Patients With Sarcoma in the Arm or Leg Isolated Limb Infusion, Pembrolizumab, infusion of melphalan and dactinomycin - Sarcoma, Myxofibrosarcoma | Phase 2 | Recruiting | Memorial Sloan Kettering Cancer Center | 30 | 2020-04-01 | 2026-04-23 |
| Talimogene Laherparepvec and Radiation Therapy in Treating Patients With Newly Diagnosed Soft Tissue Sarcoma That Can Be Removed by Surgery Biopsy Procedure, Biospecimen Collection, Magnetic Resonance Imaging - Leiomyosarcoma, Liposarcoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 40 | 2019-12-31 | 2026-11-12 |
| Study of Anlotinib Hydrochloride and Toripalimab in Subjects With Unresectable or Metastatic Undifferentiated Pleomorphic Sarcoma Anlotinib, Toripalimab, Blood Draw - Soft Tissue Sarcomas, Undifferentiated Pleomorphic Sarcoma | Phase 2 | Unknown | Di Wu | 25 | 2019-07-19 | 2019-07-10 |
| A Phase II Study of Eribulin and Pembrolizumab in Soft Tissue Sarcomas Eribulin, Pembrolizumab - Sarcoma, Liposarcoma | Phase 2 | Completed | Dana-Farber Cancer Institute | 57 | 2019-06-04 | 2025-08-28 |
| Hypofractionated Radiotherapy With Hyperthermia in Unresectable or Marginally Resectable Soft Tissue Sarcomas Hypofractionated radiotherapy, Hyperthermia - Sarcoma, Alveolar Soft Part Sarcoma | Phase 2 | Unknown | Maria Sklodowska-Curie National Research Institute of Oncology | 30 | 2018-06-01 | 2021-02-01 |
| LN-145 or LN-145-S1 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Anaplastic Thyroid Cancer, Osteosarcoma, or Other Bone and Soft Tissue Sarcomas Aldesleukin, Autologous Tumor Infiltrating Lymphocytes LN-145, Autologous Tumor Infiltrating Lymphocytes LN-145-S1 - Bone Sarcoma, Dedifferentiated Chondrosarcoma | Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 30 | 2018-04-27 | 2026-11-10 |
| CAB-AXL-ADC Safety and Efficacy Study in Adult and Adolescent Patients With Sarcoma CAB-AXL-ADC, PD-1 inhibitor - Undifferentiated Pleomorphic Sarcoma, Myxofibrosarcoma | Phase 1 / Phase 2 | Completed | BioAtla, Inc. | 245 | 2018-02-15 | 2025-09-23 |
Showing 20 of 57. Sign in to see all of them.
Histiocytoma, Malignant Fibrous (54) · Sarcoma (48) · Leiomyosarcoma (38) · Liposarcoma (34) · Sarcoma, Synovial (31) · Fibrosarcoma (27) · Neurofibrosarcoma (25) · Hemangiosarcoma (23) · Rhabdomyosarcoma (20) · Dermatofibrosarcoma (17) · Sarcoma, Alveolar Soft Part (17) · Hemangiopericytoma, Malignant (11) · Osteosarcoma (11) · Malignant mesenchymal tumor (10) · Chondrosarcoma, Extraskeletal Myxoid (9)
Neoplasms by Histologic Type (57) · Neoplasms, Connective Tissue (57) · Neoplasms, Fibrous Tissue (57) · Neoplasms, Connective and Soft Tissue (56) · Neoplasms (54) · Neoplasms, Muscle Tissue (41) · Neoplasms, Adipose Tissue (34) · Neoplasms, Nerve Tissue (27) · Nervous System Diseases (26) · Nervous System Neoplasms (26) · Neurofibroma (25) · Neuromuscular Diseases (25) · Peripheral Nervous System Diseases (25) · Peripheral Nervous System Neoplasms (25)
Doxorubicin (8) · Radiotherapy (6) · Ipilimumab (5) · Nivolumab (5) · CTLA-4 Antigen (4) · Docetaxel (4) · Gemcitabine (4) · Ifosfamide (4) · pazopanib (4) · Bevacizumab (3) · Radiation (3) · Sunitinib (3) · pembrolizumab (3) · 3-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5H-(1,3)dioxolo(4,5-f)indol-7-yl)-pyrrole-2,5-dione (2) · Biopsy (2)
National Cancer Institute (NCI) (9) · European Organisation for Research and Treatment of Cancer - EORTC (8) · M.D. Anderson Cancer Center (4) · Memorial Sloan Kettering Cancer Center (4) · Brown University (2) · Maria Sklodowska-Curie National Research Institute of Oncology (2) · Oslo University Hospital (2) · BioAtla, Inc. (1) · Celgene (1) · City of Hope Medical Center (1) · Daiichi Sankyo (1) · Dana-Farber Cancer Institute (1) · Di Wu (1) · Grupo Espanol de Investigacion en Sarcomas (1) · Gustave Roussy, Cancer Campus, Grand Paris (1)
United States (35) · France (7) · United Kingdom (7) · Belgium (6) · Canada (6) · Netherlands (5) · Denmark (4) · China (3) · Germany (3) · Norway (3) · Poland (3) · Spain (3) · Switzerland (3) · Italy (2) · Puerto Rico (2)
Ivar Hompland, MD, PhD (2) · Kjetil Boye, MD, PhD (2) · William Tap, MD (2) · A P Chen (1) · Aaron R Weiss (1) · Alba Rubio (1) · Alberto Chiappori, M.D. (1) · Allan T. van Oosterom, MD, PhD (1) · Amir A Jazaeri (1) · Antonio Casado (1) · Axel Le Cesne, MD (1) · Bradley D DeNardo, MD (1)
PMID 31401903, PMID 32827353, PMID 11705489, PMID 12528778, PMID 12957454, PMID 15010069, PMID 15177491, PMID 15592836, PMID 15659504, PMID 16528479, PMID 17095209, PMID 17109446, PMID 17336054, PMID 19088049, PMID 19451429, PMID 20471824, PMID 20932656, PMID 23382028, PMID 24215845, PMID 24637635, PMID 27502708, PMID 29370992, PMID 30249211, PMID 30410720, PMID 32554315, PMID 32702309, PMID 33203665, PMID 34515544, PMID 34722269, PMID 35115306, PMID 35934010, PMID 37523624, PMID 38236580, PMID 38579194, PMID 39343511, PMID 39356980, PMID 41836677, PMID 42194972
P30CA008748 (3), U10CA180821 (3), N01CM62206 (2), 2009 (1), N01CM62201 (1), N01CM62203 (1), P30CA012197 (1), P30CA033572 (1), R21CA117128 (1), U01CA069856 (1), U10CA031946 (1), U10CA081851 (1), U10CA098543 (1), U10CA180830 (1), U10CA180886 (1)